中国实用神经疾病杂志2017，Vol.20Issue(19)：24-28,5.DOI:10.3969/j.issn.1673-5110.2017.19.005
人尿激肽原酶治疗TOAST分型急性脑梗死的效果
Clinical effectiveness of urinary kallidinogenase on the acute ischemic strokesbased on the TOAST classification
摘要
Abstract
Objective To evaluate clinical effectiveness of urinary kallidinogenase in treatment of acute cerebral infarction (ACI).Methods One hundred and sixty-nine patients with ACI were intravenously infused urinary kallidinogenase (0.15 U/d) for 14 days besides the routine treatment.Cerebral blood flow (CBF),cerebral blood volume (CBV)and time to peak (TTP)were carried out on CTP image before and after the treatment,as well as the NIHSS score,thus to evaluate the clinical effectiveness. Color Doppler ultrasound of carotid artery,vertebral artery and heart,electrocardiogram,dynamic cranial and cervical MRI/MRA were done.Blood routine,blood biochemistries (glucose,lipid,liver and kidney function,myocardial enzymes)and coagulation rou-tine were detected.Results CBF and CBV decreased,TTP delayed in LAA group compared with SAO,CE,SOE,SUE.The NIHSS values were lower in LAA group after having treated with the urinary kallidinogenase (P <0.05).The patients had no sig-nificant adverse drug reaction.Conclusion The treatment of urinary kallidinogenase for the acute ischemic cerebral infarction had better efficacy in LAA than that in SAO and CE.关键词
人尿激肽原酶/脑梗死/TOAST分型Key words
Urinary kallidinogenase/Cerebral infarction/TOAST classification分类
医药卫生引用本文复制引用
于明,韩薇,夏海平,徐平,庄志..人尿激肽原酶治疗TOAST分型急性脑梗死的效果[J].中国实用神经疾病杂志,2017,20(19):24-28,5.基金项目
镇江市重点研发计划—社会发展重点(医卫)项目(SH2015024) （医卫）
